Table 1.
Patient, tumour and treatment characteristics, primary tumours vs metastatic lesions, each for different time periods.
| Primary tumours |
Metastatic lesions |
|||||||
|---|---|---|---|---|---|---|---|---|
| Total | 2013–2015 | 2016–2017 | 2018–2019 | Total | 2013–2015 | 2016–2017 | 2018–2019 | |
| Registrations | 2885 | 921 | 838 | 1126 | 2790 | 660 | 806 | 1324 |
| Patient characteristics | ||||||||
| Age (years): median (IQR) | 72 (66–79) | 73 (66–79) | 72 (66–79) | 72 (66–79) | 68 (61–75)a | 66 (59–74) | 68 (62–75)b | 69 (62–75)b |
| Sex: male/female (%) | 66/34 | 69/31 | 67/33 | 63/37 | 63/37a | 60/40 | 63/37 | 63/37 |
| WHO performance: 0/1/unknown (%) | 45/45/1 | 45/46/0 | 48/40/1 | 44/47/1 | 43/38/16a | 48/37/12 | 45/35/16 | 39/41/17 |
| Tumour characteristics | ||||||||
| Number of lesions treated per patient: average (ranged) | 1.08 (1–3) | 1.04 (1–2) | 1.06 (1–2) | 1.07 (1–3) | 1.26 (1–5)a | 1.20 (1–3) | 1.20 (1–3) | 1.23 (1–4) |
| Lesion size (mm): median (IQR) | 19 (13–26) | 20 (15–28) | 18 (13–25)b | 18 (13–25.5)b | 19 (12–29) | 17 (11–25) | 20 (13–30)b | 19 (12–30)b |
| Treatment characteristics | ||||||||
| Total dose (Gy): median (IQR) | 54 (48–60) | 55 (48–60) | 55 (48–60) | 54 (48–60) | 48 (30–54)a | 50 (40–55) | 48 (30–50)b | 35 (30–50)b,c |
| Number of fractions: median (IQR) | 4 (4–5) | 4 (4–5) | 4 (3–5) | 4 (3–5) | 4 (3–5)a | 5 (3–8) | 4 (3–5)b | 3 (3–5)b,c |
| Treatment duration (days): median (IQR) | 10 (7–13) | 10 (8–13) | 10 (8–13) | 9 (7–12)b,c | 8 (6–12)a | 10 (7–15) | 9 (6–12.75)b | 7 (5–10)b,c |
| Treatment preparation | ||||||||
| Imaging modalities: CT-scan/PET-CT/MRI (%)e | 62/34/1 | 58/39/1 | 61/34/2 | 66/31/1 | 56/25/16a | 60/27/11 | 56/24/17 | 54/25/17 |
| Personalized immobilization (% yes) | 79 | 84 | 85 | 69b,c | 63a | 72 | 73 | 52b,c |
| Identification of tumor motion (% yes) | 98 | 97 | 97 | 99b,c | 69a | 84 | 74b | 57b,c |
| Image fusion for target delineation (% yes) | 68 | 64 | 66 | 73b,c | 74a | 70 | 76b | 76b |
| Treatment delivery | ||||||||
| Technique: 3D-CRT/IMRT/IMRT rot (%)e | 17/8/54 | 27/12/40 | 16/9/51 | 9/5/68 | 14/4/66a | 28/7/42 | 19/3/58 | 4/3/84 |
| IGRT: CBCT/stereoscopic X-rays/combination (%)e | 70/1/5 | 67/2/6 | 65/1/8 | 76/0/1b,c | 73/1/6 | 58/2/8 | 62/0/11b | 87/0/2b,c |
| Markers (% yes) | 8 | 9 | 9 | 7 | 12a | 23 | 14b | 6b,c |
| Tumor motion compensation (% yes) | 60 | 54 | 63b | 62b | 48a | 62 | 55b | 37b,c |
Patients were allocated to the period based on the start date of the radiotherapy course.
Abbreviations: IQR: interquartile range; WHO: World Health Organisation; Gy: Gray; CT: computed tomography; PET: positron emission tomography; MRI: magnetic resonance imaging; 3D-CRT: 3-dimensional conformal radiotherapy; IMRT: intensity modulated radiotherapy; IMRT rot: rotational IMRT; IGRT: image-guided radiotherapy; CBCT: cone beam computed tomography.
Significantly different from total primary tumor.
Significantly different from 2013 to 2015.
Significantly different from 2016 to 2017.
Range of number of registrations per patient.
3 most common categories.